SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million

30 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Spero Therapeutics to Present Data at IDWeek 2021

16 Sep 2021 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Three Upcoming Investor Conferences

07 Sep 2021 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2021 15:25:43 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update

05 Aug 2021 15:01:01 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jul 2021 15:33:29 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

29 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

07 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

30 Jun 2021 17:46:29 By Nasdaq GlobeNewswire

Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206

15 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 May 2021 16:35:49 By Nasdaq GlobeNewswire

Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206

17 May 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Participate at the Berenberg Conference USA

13 May 2021 07:00:01 By Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

06 May 2021 15:01:01 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Apr 2021 15:26:03 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

29 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Mar 2021 15:31:39 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

11 Mar 2021 15:07:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

03 Mar 2021 07:30:00 By Nasdaq GlobeNewswire